Bachem Holding AG stock (CH0012530207): peptide specialist focuses on recovery and capacity after challenging 2024

Bachem Holding AG, a key peptide and oligonucleotide manufacturer, has outlined 2024 results and a cautious near?term outlook while reaffirming its long?term growth ambitions. The Swiss group remains closely watched by investors interested in biotech supply chains.

Bachem Holding AG, a Swiss specialist in peptides and oligonucleotides for pharma and biotech customers, reported a drop in 2024 sales and earnings but reiterated its long?term growth strategy and capacity expansion plans, according to a full?year release published on March 18, 2025 by the company’s investor relations team (Bachem investor update as of 03/18/2025). The group highlighted weaker demand from some large customers in 2024, while pointing to a project pipeline that it expects to support gradual recovery over the next few years, as summarized by a same?day coverage from a Swiss financial news outlet (Finanz und Wirtschaft as of 03/18/2025).

As of: 05/20/2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Bachem Holding AG
• Sector/industry: Pharmaceutical ingredients / biotech manufacturing
• Headquarters/country: Bubendorf, Switzerland
• Core markets: Europe, North America and Asia for pharma and biotech customers
• Key revenue drivers: Custom and generic peptides, oligonucleotides, CDMO services
• Home exchange/listing venue: SIX Swiss Exchange (ticker: BANB)
• Trading currency: Swiss franc (CHF)

Bachem Holding AG: core business model

Bachem Holding AG operates as a contract development and manufacturing organization, or CDMO, focused on complex peptides and increasingly on oligonucleotides for pharmaceutical and biotechnology customers. The company’s business model centers on long?term relationships with drug developers that need specialized chemistry and large?scale production capabilities, as outlined in its 2024 annual report published on March 18, 2025 (Bachem annual report as of 03/18/2025). Bachem generates revenue from both commercial products already on the market and from development?stage projects that may later transition into commercial supply contracts.

The company divides its activities into two main segments: a commercial segment that produces established generic and proprietary peptide products, and a custom development and manufacturing segment that supports customers from pre?clinical work through large clinical trials and market launch. This mix gives Bachem exposure to recurring demand for certain established molecules while also offering upside from new drug approvals, according to the same 2024 annual report released in March 2025 (Bachem annual report as of 03/18/2025). The business can be sensitive to the timing of customer orders and regulatory milestones, which can make quarterly performance volatile.

In addition to manufacturing, Bachem offers analytical services and technical support to help optimize peptide and oligonucleotide processes. These services are usually embedded into broader supply relationships and can deepen customer ties over time. For US?focused investors, Bachem’s model provides indirect exposure to innovative therapeutics and drug pipelines without relying on the binary clinical outcomes that often dominate smaller biotech stocks. Instead, the company’s risk profile is more tied to capacity utilization, pricing, and its ability to remain a preferred partner for complex chemistries.

Main revenue and product drivers for Bachem Holding AG

Peptide manufacturing remains Bachem’s largest revenue driver, spanning generic peptide APIs, custom peptides for specific branded drugs, and research?grade materials. Demand comes from a wide range of therapeutic areas, including metabolic diseases, oncology and endocrine disorders, according to the 2024 annual results communication issued on March 18, 2025 (Bachem investor update as of 03/18/2025). The company benefits when customers advance from early research into later?stage clinical trials, as required quantities and batch complexity typically increase.

Oligonucleotides, short DNA or RNA fragments used in certain genetic medicines and diagnostics, represent a newer but strategically important pillar. Bachem has been investing in capabilities for these products and views them as a growth area for the next decade, as emphasized in its strategy presentation accompanying the 2024 annual report, released on March 18, 2025 (Bachem strategy update as of 03/18/2025). Although oligonucleotides currently account for a smaller share of sales than peptides, they may carry higher growth rates if more therapies reach the market.

Another important driver is the company’s role as a CDMO for complex, high?volume projects, where large customers outsource manufacturing instead of building in?house capacity. In 2024, Bachem noted that some sizeable orders had been delayed or reduced, contributing to weaker reported results, as detailed in the 2024 results press release published on March 18, 2025 (Bachem investor update as of 03/18/2025). The company highlighted that the underlying project portfolio remained broad, suggesting that the timing of orders rather than loss of customers was a key factor behind the decline.

Geographically, Bachem’s revenue base is diversified, with significant contributions from European and North American pharmaceutical clients. The company operates production sites in Switzerland, the United States and other locations to serve global demand efficiently, as described in a corporate profile on its website updated in February 2025 (Bachem company profile as of 02/10/2025). For US investors, Bachem’s US facilities link the group to the domestic drug development ecosystem and support supply chains for therapies targeting the US market.

Industry trends and competitive position

The peptide and oligonucleotide manufacturing market has expanded alongside growth in biologics and complex small molecules, with customers favoring partners that can deliver consistent quality at scale. Market research cited by Bachem in its 2024 annual report, released on March 18, 2025, points to a medium?term expansion of outsourced development and manufacturing services, particularly in high?value APIs (Bachem annual report as of 03/18/2025). In this environment, the company competes with other specialized CDMOs as well as larger diversified contract manufacturers.

Bachem positions itself as a technology?driven leader with decades of know?how in peptide synthesis and purification. Its competitive approach includes investing in automation, process optimization and capacity expansions in Switzerland and the United States, which are designed to support large?scale commercial projects, according to the strategy update published on March 18, 2025 (Bachem strategy update as of 03/18/2025). However, the company also faces pressure to maintain high utilization rates and manage capital expenditures carefully, particularly in years when demand is temporarily softer.

Regulatory expectations from authorities such as the FDA and EMA play a central role in shaping competitive dynamics. Manufacturers must demonstrate robust quality systems and consistent compliance across sites. Bachem pointed out in its 2024 annual report that past inspections at key facilities had supported its reputation with customers, while it continues to invest in quality and digitalization initiatives to meet evolving standards, as described in the same report dated March 18, 2025 (Bachem annual report as of 03/18/2025). This regulatory track record is a relevant factor for investors assessing long?term contract stability.

Why Bachem Holding AG matters for US investors

Although Bachem is listed on the SIX Swiss Exchange rather than a US venue, its operations and customer base give it significant links to the US pharmaceutical and biotech market. The company operates production capacity in the United States and counts American drug developers among its important customers, according to its company overview updated in February 2025 (Bachem company profile as of 02/10/2025). For US investors with access to international markets, the stock offers exposure to the broader trend of outsourcing complex drug manufacturing.

From a portfolio perspective, Bachem can behave differently from early?stage biotech names that rely on binary clinical readouts. Its revenue stream depends more on a diversified set of customer projects and on the utilization of installed manufacturing capacity. This profile may appeal to investors seeking a way to participate in innovation across multiple pipelines rather than betting on a single molecule. At the same time, results can still be cyclical due to the order?driven nature of the business, as the 2024 performance indicated in the annual results release from March 18, 2025 (Bachem investor update as of 03/18/2025).

Currency is another consideration for US investors. Because Bachem reports in Swiss francs and its shares trade in CHF on the SIX Swiss Exchange, the total return for a US?based holder will also reflect movements in the USD/CHF exchange rate. In addition, access depends on the investor’s brokerage platform and its ability to trade on Swiss markets or in over?the?counter instruments. These practical factors sit alongside the usual company?specific aspects such as growth prospects, margin development and capital expenditure needs.

Conclusion

Bachem Holding AG remains a specialized player in peptide and oligonucleotide manufacturing, serving pharmaceutical and biotech customers across Europe, North America and Asia. The company’s 2024 results, released on March 18, 2025, highlighted how order timing and softer demand from some large clients can weigh on short?term performance, even when the underlying project pipeline is intact (Bachem investor update as of 03/18/2025). Management has reiterated its commitment to capacity investments and technology enhancements, especially in oligonucleotides, aiming to position the group for future growth. For US?oriented investors able to access Swiss?listed stocks, Bachem offers indirect exposure to a broad set of innovative therapies and drug candidates, but its results can fluctuate with capacity utilization, client ordering patterns and regulatory demands. Careful attention to upcoming earnings updates, project wins and capital expenditure plans will remain important for those following the stock.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.